Trial Profile
Extended Use of CS 7017 Upon Completion of Participation in a Clinical Study of CS-7017 in Subjects With Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Efatutazone (Primary)
- Indications Cancer
- Focus Biomarker; Therapeutic Use
- Sponsors Daiichi Sankyo Inc
- 21 Aug 2017 New trial record